Oslo, Oct 1, 2018 - Navamedic ASA (OSE: NAVA) today announces that Tom Rönnlund has tendered his resignation as CEO of Navamedic ASA and will leave the company at the end of 2018 to take up a position with the Swedish probiotic company Probi AB.
"Tom has been a driving force in the development of the company and leading it through challenging times. The platform Tom has built together with the team over the past three years puts us in a good position to further grow the company. On behalf of Navamedic, I want to express my thanks to Tom for his efforts and wish him success in his future endeavours" says Kathrine Gamborg Andreassen, Chair of the Board.
Tom Rönnlund will join Probi AB, a Swedish publicly traded bioengineering company.
"To leave Navamedic has been a very difficult decision. I am proud of what we as a team have accomplished during a transformational period for the company. We have positioned ourselves for a bright future through new and innovative growth products with great potential and I am confident that the Navamedic team will succeed in capitalizing on all the opportunities ahead of us," says Tom Rönnlund.
The search for a new CEO has been initiated and Rönnlund will remain CEO of Navamedic until the end of 2018.
For further information, please contact:
Kathrine Gamborg Andreassen, Chair of the Board, Navamedic
Telephone: +47 951 78 680
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
About Navamedic ASA
Navamedic ASA is a Norwegian medtech and pharmaceutical products company, delivering products to patients, hospitals and pharmacies in the Nordic and select European markets. The Group's Medtech business has developed and is currently introducing the next generation of digital urine meter Sippi®. Navamedic's Pharma and Healthcare business is a distributor of products supplied by a number of pharmaceutical manufacturers. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA). www.navamedic.com